A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy with or without Brentuximab Vedotin plus Nivolumab Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma »